News
Merck’s Keytruda, with more than 40 approved indications, hasn’t yet been able to crack specifically into ovarian cancer. But with promising early results from a phase 3 study in certain ...
Hosted on MSN1mon
Merck reports mixed results from Keytruda ovarian cancer study - MSNMerck (NYSE:MRK) said a Phase 3 study of its drug Keytruda in the treatment of a certain type of ovarian cancer met its primary endpoint of progression-free survival, but not its secondary ...
Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ovarian cancer, including patients with PD-L1–positive tumors.
Keytruda is not approved to treat ovarian cancer. Sunday, Merck announced the first presentation of data from the Phase 2 waveLINE-007 trial evaluating zilovertamab vedotin in combination with ...
Merck (NYSE:MRK) announced Thursday that its bestselling therapy, Keytruda, as part of a combination regimen, reached the primary endpoint in a Phase 3 trial for a certain type of ovarian cancer.
Merck’s Keytruda shows promise in ovarian cancer trial. RAHWAY, N.J. – Merck & Co., Inc., a global healthcare leader, announced positive results from its Phase 3 KEYNOTE-B96 trial, which could ...
Merck & Co – known as MSD outside the US and Canada – has shared promising results from a late-stage study of its anti-PD-1 therapy Keytruda (pembrolizumab) in ovarian cancer. The phase 3 KEYNOTE-B96 ...
Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat head and neck cancers.
References: Merck announces phase 3 KEYNOTE-B96 trial met primary endpoint of progression-free survival (PFS) in patients with platinum-resistant recurrent ovarian cancer whose tumors expressed PD ...
Merck’s Keytruda shows promise in ovarian cancer trial. RAHWAY, N.J. – Merck & Co., Inc., a global healthcare leader, announced positive results from its Phase 3 KEYNOTE-B96 trial, which could ...
Ovarian cancer is a leading cause of cancer death among women, with an estimated 324,603 new cases and approximately 206,956 deaths globally in 2022. In the U.S., approximately 20,890 new cases ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results